Resources for Patients
GBM AGILE offers the ability to rapidly deliver new and improved treatments to patients facing a diagnosis of glioblastoma. If you or someone you know may be interested in participating in the GBM AGILE clinical trial, you may locate a trial site near you and connect with its clinical trial team for evaluation and enrollment support. Additionally, you can learn more from viewing the GBM AGILE frequently asked questions.
Important Statistics on Glioblastoma
- Malignant brain tumors occur slightly more often in males than females.
- Despite advances in treatment, researchers still don’t understand what causes GBMs, but they are not hereditary!
- An estimated 84,170 people in the United States will receive a primary brain tumor diagnosis in 2021; 25,130 will be malignant and nearly 49% will be GBM.
- Glioblastoma can occur at any age, but tends to occur more often in older adults (60+).
- GBM is much more common in adults than in children.
- Grade IV tumors, primarily glioblastoma, are the highest and most aggressive grade of tumors.